# An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

> **NCT00939783** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 649 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Dimebon

## Key facts

- **NCT ID:** NCT00939783
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 649 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939783, "An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00939783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*